“During the first quarter of 2024, we continued to execute on our two strategic paths for TOUR006, including the initiation of our Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. We believe TOUR006 offers multiple pipelines in a single product with the potential to address significant unmet medical needs in TED, ASCVD, and other autoantibody and inflammation-driven diseases,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. “We are excited about the ongoing progress of our clinical programs as well as the opportunity to expand into additional indications in 2024 and beyond.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- 3 Best Stocks to Buy Now, 3/26/2024, According to Top Analysts
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Tourmaline Bio price target raised to $74 from $43 at Truist
- Tourmaline Bio might see weakness today after Roche MG data, says Truist
- Tourmaline Bio sinks after Chugai myasthenia gravis study failure